Nucleome Therapeutics Revenue
Biotechnology Research • 
Oxford, England, United Kingdom • 51-100 Employees
Nucleome Therapeutics revenue & valuation
| Annual revenue | $4,705,525 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $15,100,000 |
| Total funding | $42,000,000 |
Key Contacts at Nucleome Therapeutics
Jonny Wray
Chief Technology Officer
Paul Brackstone
Director Of Facilities, Operations & Health And Safety
Rachael Nimmo
Team Leader & Director - Drug Discovery
Mark Bodmer
Chief Executive Officer
Justyna Kozlowska
Associate Director, Computational Biology
James Heward
Director - Functional Genomics
Davide Lucchesi
Associate Director
Chantal Hargreaves
Director - Drug Discovery
Polly Weston
Director Of Administration
Company overview
| Headquarters | Oxford, England, United Kingdom |
| Phone number | +4412109297 |
| Website | |
| Founded | 2019 |
| Employees | 51-100 |
| Socials |
Nucleome Therapeutics Email Formats
Nucleome Therapeutics uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@nucleome.com), used 65.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@nucleome.com | 65.1% |
{first name}.{last name} | john.doe@nucleome.com | 34.9% |
About Nucleome Therapeutics
Nucleome was founded in 2019. The precision of its 3D genomics technology has the potential to improve drug discovery success rates both by discovering genetically-validated medicines, and by more accurately identifying patients who are likely to benefit from treatments. Nucleome’s platform can be applied to multiple disease indications and cell types, with an initial focus on inflammatory conditions. In addition to building its own pipeline, the company is forging external collaborations in target discovery, target validation, and patient stratification. Nucleome was founded by leading experts in gene regulation from the University of Oxford. The Company is backed by a world-class syndicate of investors that includes M Ventures, the strategic corporate venture capital arm of Merck KGaA; Johnson and Johnson Innovation-JJDC, Inc. (“JJDC”), the strategic venture capital arm of Johnson & Johnson; Pfizer Ventures, the venture group of Pfizer; British Patient Capital; and founding investor Oxford Science Enterprises.
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Nucleome Therapeutics has 11 employees across 9 departments.
Departments
Number of employees
Nucleome Therapeutics Tech Stack
Discover the technologies and tools that power Nucleome Therapeutics's digital infrastructure, from frameworks to analytics platforms.
UI frameworks
Video players
Form builders
JavaScript libraries
JavaScript libraries
CDN
Analytics
Font scripts
JavaScript libraries
Miscellaneous
Security
Spain
Poland
United States
Frequently asked questions
4.8
40,000 users
